Clinical Trials Browser

Phase 1 × Colorectal Neoplasms × budigalimab × Clear all

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03821935 2025-05-25

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

364 enrolled

BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01946074 2023-12-15

A Study of ABT-165 in Subjects With Solid Tumors

Phase 1 Completed

101 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT03035279 2020-02-20

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Phase 1 Terminated

29 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

Clinical Trials

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of ABT-165 in Subjects With Solid Tumors

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer